Research

Focus on the pharmaceutical and biotech industry
Lara Sullivan Discusses SpringWorks Therapeutics

Lara Sullivan Discusses SpringWorks Therapeutics

Lara Sullivan, MD, President and Founder at SpringWorks Therapeutics discusses her company, which was originally conceived by Pfizer as a way to advance investigational therapies that may hold promise for underserved patients. SpringWorks Therapeutics’ collaborative...

Philippe M. Maitre Discusses Onxeo

Philippe M. Maitre Discusses Onxeo

Philippe M. Maitre, Executive Vice President, US Operations discusses Onxeo and the company's focus on orphan oncology products. Onxeo was created through the merger of BioAlliance Pharma, a French innovative company based in Paris specializing in the development of...

Actinium Pharma Provides Update on Actimab-A Phase 2 Clinical Trial for AML

Actinium’s Iomab-B in a Pivotal Phase 3 SIERRA Trial

Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses the potential market for Iomab-B. Iomab-B via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells. BC8 is linked to...

The MOA of Senicapoc: A Gardos Channel Blocker

The MOA of Senicapoc: A Gardos Channel Blocker

Lara Sullivan, MD, President and Founder at SpringWorks Therapeutics discusses the mechanism of action of Senicapoc (a Gardos channel blocker), an emerging treatment for Hereditary Xerocytosis, a genetic disorder in which red blood cells become dehydrated due to loss...

Ovid Therapeutics’ Focus

Ovid Therapeutics’ Focus

Jeremy Levin, Chairman and Chief Executive Officer of Ovid Therapeutics, discusses his company's focus and how it is developing drugs for patients with rare disorders.

Neonatal Onset Multisystem Inflammatory Disease (NOMID) Overview

Neonatal Onset Multisystem Inflammatory Disease (NOMID) Overview

Len Walt, Vice President, Head of Medical Affairs, Sobi in North America, discusses neonatal onset multisystem inflammatory disease (NOMID), a disorder that causes persistent inflammation and tissue damage primarily affecting the nervous system, skin, and joints....

Targeted Therapies for Neurology Patients

Targeted Therapies for Neurology Patients

Jeremy Levin, Chairman and Chief Executive Officer of Ovid Therapeutics, discusses his company's focus on developing targeted therapies for patients with rare neurological disorders. Ovid Therapeutics is a New York-based biopharmaceutical company using its...

Challenges of Diagnosing Rare Diseases

Challenges of Diagnosing Rare Diseases

Amit Rakhit, MD, Chief Medical and Portfolio Officer of Ovid Therapeutics, discusses the challenges of diagnosing rare disorders in general, and Fragile X and Angelman syndromes specifically. Family physicians, pediatricians, and other primary health care...

The Orphan Drug Act: What Does “Orphan” Mean?

The Orphan Drug Act: What Does “Orphan” Mean?

Douglas Paul, PharmD, PhD discusses the Orphan Drug Act and what the term "Orphan" means in context of the the Rare Disease industry, especially considering that much of the Rare Disease pipeline is for Oncology products. The Orphan Drug Act was first enacted in the...

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.